FindTrial
Sign In

Real world outcome of 1st line atezolizumab in extensive stage small cell lung cancer

Real world outcome of 1st line atezolizumab in extensive stage small cell lung cancer (RW_ACE)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0006818
Enrollment
100
Registered
2021-12-08
Start date
2021-12-29
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who were diagnosed as extensive stage SCLC by histocytologic confirmation 2. Patients who are planning to initiate 1st line atezolizumab for SCLC Or Patients who are already under treatment with 1st line atezolizumab for SCLC will also be eligible to current study 3. Male or female adult patients aged 19 years old and above 4. The participants who provide written informed consent for the study

Exclusion criteria

Exclusion criteria: 1. Patients who already completed atezolizumab treatment

Design outcomes

Primary

MeasureTime frame
1-year overall survival (OS) rate of 1st line atezolizumab in extensive stage small cell lung cancer (ES-SCLC) patients of South Korea—

Secondary

MeasureTime frame
PFS, OS, 18- & 24-month OS rate, duration of treatment (DoT), duration of response (DR), disease control rate (DCR), time to progression (TTP) of atezolizumab;Safety of 1st line atezolizumab in ES-SCLC patients;Role and pattern of additional radiotherapy treating SCLC in routine clinical practice—

Countries

Korea, Republic of

Contacts

Public ContactJae Cheol Lee

Asan Medical Center

jclee@amc.seoul.kr+82-2-3010-3208

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026